SOURCE: Active Biotech

November 07, 2007 02:40 ET

INITIATION OF ENROLLMENT IN PIVOTAL PHASE III CLINICAL STUDY OF ORAL LAQUINIMOD FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS

LUND, SWEDEN--(Marketwire - November 7, 2007) -



For further information, please contact:

Dan Suesskind,          Teva Pharmaceutical Industries Ltd.  972-2-941-1717
Chief Financial Officer

George Barrett,
Corp. E. V.P. - Global  Teva Pharmaceutical Industries Ltd.  (215) 591-3030
 pharmaceutical Markets
Chief Executive Officer Teva North America

Liraz Kalif /           Teva Pharmaceutical Industries Ltd.  972-3-926-7281
Kevin Mannix,           Teva North America                   (215) 591-8912
Investor Relations

Sven Andréasson         Active Biotech                      +46 46 19 20 49
President & CEO


Tomas Leanderson        Active Biotech                      +46 46 19 20 95
Chief Scientific Officer

Cecilia Hofvander       Active Biotech                      +46 46 19 11 22
Manager Corporate Communication


INITIATION OF ENROLLMENT IN PIVOTAL PHASE III CLINICAL STUDY -- http://hugin.info/1002/R/1166589/228490.pdf



Copyright © Hugin ASA 2007. All rights reserved.

Contact Information